Status: Not yet recruiting
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma (including patients previous treated with a PARP inhibitor).
Participants needed: 132
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Xiaohua Wu MDUpdated: Jul 29, 2022
Eligibility criteria
The patient voluntarily joined the study and signed the informed consent [+17]
Prior malignancy unless curatively treated and disease-free for > 5 years prior... [+18]